"10.1371_journal.pone.0067888","plos one","2013-07-09T00:00:00Z","Frances E Pearson; Celia L McNeilly; Michael L Crichton; Clare A Primiero; Sally R Yukiko; Germain J P Fernando; Xianfeng Chen; Sarah C Gilbert; Adrian V S Hill; Mark A F Kendall","Delivery of Drugs and Genes Group (D2G2), Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia; The Jenner Institute, The University of Oxford, Oxford, United Kingdom; Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia; Vaxxas Pty Ltd, Australian Institute for Bioengineering and Nanotechnology, Brisbane, Queensland, Australia","Conceived and designed the experiments: FEP CLM MLC GJPF XC MAFK AVSH. Performed the experiments: FEP CLM MLC CAP SRY XC. Analyzed the data: FEP CLM MLC CAP. Wrote the paper: FEP. Made the MVA vaccine: SCG.","Authors MLC, GJPF, XC and MAFK are either inventors or contributors to a patent filings related to the NanopatchTM technology, that is now licensed to Vaxxas Pty Ltd. These are detailed in Supporting Information - Table S2. Authors MLC, SRY, GJPF and MAFK have employment with Vaxxas. MAFK is a member of the Vaxxas board. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","07","Frances E Pearson","FEP",10,TRUE,7,6,4,1,TRUE,TRUE,FALSE,0,NA,FALSE
